Contraceptive vaccines

Eileen A. McLaughlin, Michael K. Holland, R. J. Aitken

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The control of human fertility would be revolutionised by the development of a safe, effective, long-acting contraceptive vaccine. The pursuit of this objective has involved the selection of appropriate targets within the reproductive process that are amenable to interference with antibodies. To date, three major targets have been researched. The zona pellucida (ZP) plays key roles in folliculogenesis, fertilisation and early development, and is comprised of powerful cell-specific antigens. The induction of infertility requires high ZP antibody titres that are difficult to maintain without inducing ovarian pathology characterised by a premature loss of primordial follicles. As a premature menopause would be a high price to pay for long-term contraception, this approach to a vaccine cannot progress until the cause of the ovarian pathology has been resolved. Sperm surface antigens represent another promising approach to contraceptive vaccine development. While there is some clinical data to support the likely efficacy of this strategy, none of the gamete-specific molecules characterised to date have fulfilled this promise. Anti-human chorionic gonadotropin (hCG) vaccines terminate pregnancy by preventing the maternal recognition of pregnancy. This vaccine has reached the stage of clinical trials, and preliminary indications are that the approach is safe and potentially effective. However, reliability may be an issue, given the observed inter-individual variability in antibody generation. The future of contraceptive vaccine development will clearly involve a continuation of the intense search for suitable targets and the development of improved immunisation procedures that exploit the latest innovations in vaccine technology.

Original languageEnglish
Pages (from-to)829-841
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume3
Issue number5
DOIs
Publication statusPublished - Aug 2003
Externally publishedYes

Fingerprint

Contraceptive Vaccines
Vaccines
Zona Pellucida
Pathology
Contraception
Antibodies
Premature Menopause
Immunization
Pregnancy
Chorionic Gonadotropin
Surface Antigens
Fertilization
Germ Cells
Infertility
Spermatozoa
Innovation
Mothers
Clinical Trials
Technology
Antigens

Cite this

McLaughlin, Eileen A. ; Holland, Michael K. ; Aitken, R. J. / Contraceptive vaccines. In: Expert Opinion on Biological Therapy. 2003 ; Vol. 3, No. 5. pp. 829-841.
@article{8c45fd95e9004e1f8e7e9731bd8b483d,
title = "Contraceptive vaccines",
abstract = "The control of human fertility would be revolutionised by the development of a safe, effective, long-acting contraceptive vaccine. The pursuit of this objective has involved the selection of appropriate targets within the reproductive process that are amenable to interference with antibodies. To date, three major targets have been researched. The zona pellucida (ZP) plays key roles in folliculogenesis, fertilisation and early development, and is comprised of powerful cell-specific antigens. The induction of infertility requires high ZP antibody titres that are difficult to maintain without inducing ovarian pathology characterised by a premature loss of primordial follicles. As a premature menopause would be a high price to pay for long-term contraception, this approach to a vaccine cannot progress until the cause of the ovarian pathology has been resolved. Sperm surface antigens represent another promising approach to contraceptive vaccine development. While there is some clinical data to support the likely efficacy of this strategy, none of the gamete-specific molecules characterised to date have fulfilled this promise. Anti-human chorionic gonadotropin (hCG) vaccines terminate pregnancy by preventing the maternal recognition of pregnancy. This vaccine has reached the stage of clinical trials, and preliminary indications are that the approach is safe and potentially effective. However, reliability may be an issue, given the observed inter-individual variability in antibody generation. The future of contraceptive vaccine development will clearly involve a continuation of the intense search for suitable targets and the development of improved immunisation procedures that exploit the latest innovations in vaccine technology.",
keywords = "Contraception, Human chorionic gonadotropin, Oocytes, Spermatozoa, Zona pellucida",
author = "McLaughlin, {Eileen A.} and Holland, {Michael K.} and Aitken, {R. J.}",
year = "2003",
month = "8",
doi = "10.1517/14712598.3.5.829",
language = "English",
volume = "3",
pages = "829--841",
journal = "Expert Opinions in Biological Therapies",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

Contraceptive vaccines. / McLaughlin, Eileen A.; Holland, Michael K.; Aitken, R. J.

In: Expert Opinion on Biological Therapy, Vol. 3, No. 5, 08.2003, p. 829-841.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Contraceptive vaccines

AU - McLaughlin, Eileen A.

AU - Holland, Michael K.

AU - Aitken, R. J.

PY - 2003/8

Y1 - 2003/8

N2 - The control of human fertility would be revolutionised by the development of a safe, effective, long-acting contraceptive vaccine. The pursuit of this objective has involved the selection of appropriate targets within the reproductive process that are amenable to interference with antibodies. To date, three major targets have been researched. The zona pellucida (ZP) plays key roles in folliculogenesis, fertilisation and early development, and is comprised of powerful cell-specific antigens. The induction of infertility requires high ZP antibody titres that are difficult to maintain without inducing ovarian pathology characterised by a premature loss of primordial follicles. As a premature menopause would be a high price to pay for long-term contraception, this approach to a vaccine cannot progress until the cause of the ovarian pathology has been resolved. Sperm surface antigens represent another promising approach to contraceptive vaccine development. While there is some clinical data to support the likely efficacy of this strategy, none of the gamete-specific molecules characterised to date have fulfilled this promise. Anti-human chorionic gonadotropin (hCG) vaccines terminate pregnancy by preventing the maternal recognition of pregnancy. This vaccine has reached the stage of clinical trials, and preliminary indications are that the approach is safe and potentially effective. However, reliability may be an issue, given the observed inter-individual variability in antibody generation. The future of contraceptive vaccine development will clearly involve a continuation of the intense search for suitable targets and the development of improved immunisation procedures that exploit the latest innovations in vaccine technology.

AB - The control of human fertility would be revolutionised by the development of a safe, effective, long-acting contraceptive vaccine. The pursuit of this objective has involved the selection of appropriate targets within the reproductive process that are amenable to interference with antibodies. To date, three major targets have been researched. The zona pellucida (ZP) plays key roles in folliculogenesis, fertilisation and early development, and is comprised of powerful cell-specific antigens. The induction of infertility requires high ZP antibody titres that are difficult to maintain without inducing ovarian pathology characterised by a premature loss of primordial follicles. As a premature menopause would be a high price to pay for long-term contraception, this approach to a vaccine cannot progress until the cause of the ovarian pathology has been resolved. Sperm surface antigens represent another promising approach to contraceptive vaccine development. While there is some clinical data to support the likely efficacy of this strategy, none of the gamete-specific molecules characterised to date have fulfilled this promise. Anti-human chorionic gonadotropin (hCG) vaccines terminate pregnancy by preventing the maternal recognition of pregnancy. This vaccine has reached the stage of clinical trials, and preliminary indications are that the approach is safe and potentially effective. However, reliability may be an issue, given the observed inter-individual variability in antibody generation. The future of contraceptive vaccine development will clearly involve a continuation of the intense search for suitable targets and the development of improved immunisation procedures that exploit the latest innovations in vaccine technology.

KW - Contraception

KW - Human chorionic gonadotropin

KW - Oocytes

KW - Spermatozoa

KW - Zona pellucida

UR - http://www.scopus.com/inward/record.url?scp=0042671195&partnerID=8YFLogxK

U2 - 10.1517/14712598.3.5.829

DO - 10.1517/14712598.3.5.829

M3 - Review article

VL - 3

SP - 829

EP - 841

JO - Expert Opinions in Biological Therapies

JF - Expert Opinions in Biological Therapies

SN - 1471-2598

IS - 5

ER -